MB12066 200mg

DRUG2 trials

Sponsors

Yungjin Pharm. Co., Ltd.

Conditions

Metabolic SyndromeNonalcoholic Fatty Liver Disease

Phase 1

Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male Volunteers

CompletedNCT02338856

Yungjin Pharm. Co., Ltd.Metabolic Syndrome

Start: 2015-01-31End: 2015-02-28Updated: 2017-12-21

Phase 2

Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis

TerminatedNCT02029586

Yungjin Pharm. Co., Ltd.Nonalcoholic Fatty Liver Disease

Start: 2013-01-31End: 2014-11-30Updated: 2017-12-21